Prehospital pulse-dose glucocorticoid in patients with STEMI – the PULSE-MI 2 trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524320-21-00

Enrollment

5204

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment Elevation Myocardial Infarction

Brief summary

All-cause mortality

Detailed description

Cardiovascular mortality, Spontaneous myocardial infarction, Admission for heart failure, All-cause mortality or admission for heart failure, Cardiovascular mortality or admission for heart failure, Recurrent non-fatal cardiovascular events (spontaneous myocardial infarction and admission for heart failure) with death treated as a terminal event

Interventions

DRUGNatriumchlorid ”Noridem”

DRUGsolvens til parenteral anvendelse/injektionsvæske

DRUGopløsning

DRUGSOLU-MEDROL 125 mg pulver och vätska till injektionsvätska

DRUGlösning

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
All-cause mortality	—

Secondary

Measure	Time frame
Cardiovascular mortality, Spontaneous myocardial infarction, Admission for heart failure, All-cause mortality or admission for heart failure, Cardiovascular mortality or admission for heart failure, Recurrent non-fatal cardiovascular events (spontaneous myocardial infarction and admission for heart failure) with death treated as a terminal event	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 12, 2026